Exact Sciences extends it collaboration with Mayo Clinic

Special to The Freeman

Feb. 6, 2015

MADISON —Exact Sciences has extended its collaboration with the Mayo Clinic by five years, resulting in broadened efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract, according to the Friday announcement.

As part of the agreement, work will continue with David Ahlquist, M.D., a Mayo Clinic gastroenterologist, and his lab at Mayo Clinic, and Exact Sciences will continue to have rights to certain intellectual property, including patents, know-how and new markers.

The original agreement between the Madison-based company and the Mayo Clinic led to the development of Cologuard, which the U.S. Food and Drug Administration approved Aug. 11, according to the announcement. Cologuard is the first and only FDA-approved stool DNA-based colorectal cancer screening test.

“By expanding our relationship with Mayo Clinic, we have an opportunity to build on our shared successes and continue looking for new opportunities to take on some of the deadliest forms of cancer,” said Kevin Conroy, CEO and chairman of Exact Sciences, in a statement. “This collaboration and our ability to leverage both institutions’ distinctly different strengths is unique in American industry. But our ambitions cannot end with Cologuard. We expect our collaboration to continue producing breakthroughs that can change patients’ lives.”

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. For more information, go to www.exactsciences.com.

Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, go to www.mayoclinic.org.